Correlation between decreased CSF α-synuclein and Aβ1-42 in Parkinson disease

Neurobiology of Aging

Volumn 36, Issue 1, 2015, Pages 476-484

  Buddhala, Chandana ^a   Campbell, Meghan C ^a,b   Perlmutter, Joel S ^a,b   Kotzbauer, Paul T ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

A 1 42; Cerebrospinal fluid; Imaging; Nondemented; Parkinson's disease; PiB; Tau; Synuclein

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E4; TAU PROTEIN; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); APOLIPOPROTEIN E; PEPTIDE FRAGMENT;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSS-SECTIONAL STUDY; DISEASE SEVERITY; FEMALE; HUMAN; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; NEUROPSYCHOLOGICAL TEST; PARKINSON DISEASE; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN METABOLISM; RECEIVER OPERATING CHARACTERISTIC; CEREBROSPINAL FLUID; COGNITION; GENETICS; GENOTYPE; METABOLISM; PATHOPHYSIOLOGY; PSYCHOLOGY; PSYCHOMOTOR PERFORMANCE;

AGED; ALPHA-SYNUCLEIN; AMYLOID BETA-PEPTIDES; APOLIPOPROTEINS E; COGNITION; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; PEPTIDE FRAGMENTS; PSYCHOMOTOR PERFORMANCE; TAU PROTEINS;

EID: 84920482878     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2014.07.043     Document Type: Article

References (77)

1. Aarsland D., Kurz M.W. The epidemiology of dementia associated with Parkinson disease. J.Neurol. Sci. 2010, 289:18-22.
2. Aerts M.B., Esselink R.A., Abdo W.F., Bloem B.R., Verbeek M.M. CSF alpha-synuclein does not differentiate between parkinsonian disorders. Neurobiol. Aging 2012, 33:430.e1-430.e3.
3. Alves G., Bronnick K., Aarsland D., Blennow K., Zetterberg H., Ballard C., Kurz M.W., Andreasson U., Tysnes O.B., Larsen J.P., Mulugeta E. CSF amyloid-beta and tau proteins, and cognitive performance, in early and untreated Parkinson's disease: the Norwegian ParkWest study. J.Neurol. Neurosurg. Psychiatry 2010, 81:1080-1086.
4. Argyriou A., Dermentzaki G., Papasilekas T., Moraitou M., Stamboulis E., Vekrellis K., Michelakakis H., Stefanis L. Increased dimerization of alpha-synuclein in erythrocytes in Gaucher disease and aging. Neurosci. Lett. 2012, 528:205-209.
5. Armstrong R., Kotzbauer P., Perlmutter J., Campbell M., Hurth K., Schmidt R., Cairns N. Aquantitative study of α-synuclein pathology in fifteen cases of dementia associated with Parkinson disease. J.Neural Transm. 2014, 121:171-181.
6. Ballard C., Ziabreva I., Perry R., Larsen J.P., O'Brien J., McKeith I., Perry E., Aarsland D. Differences in neuropathologic characteristics across the Lewy body dementia spectrum. Neurology 2006, 67:1931-1934.
7. Borghi R., Marchese R., Negro A., Marinelli L., Forloni G., Zaccheo D., Abbruzzese G., Tabaton M. Full length alpha-synuclein is present in cerebrospinal fluid from Parkinson's disease and normal subjects. Neurosci. Lett. 2000, 287:65-67.
8. Braak H., Ghebremedhin E., Rub U., Bratzke H., Del Tredici K. Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res. 2004, 318:121-134.
9. Burack M.A., Hartlein J., Flores H.P., Taylor-Reinwald L., Perlmutter J.S., Cairns N.J. Invivo amyloid imaging in autopsy-confirmed Parkinson disease with dementia. Neurology 2010, 74:77-84.
10. Burke W.J., Miller J.P., Rubin E.H., Morris J.C., Coben L.A., Duchek J., Wittels I.G., Berg L. Reliability of the Washington University clinical dementia rating. Arch. Neurol. 1988, 45:31-32.
11. Campbell M.C., Markham J., Flores H., Hartlein J.M., Goate A.M., Cairns N.J., Videen T.O., Perlmutter J.S. Principal component analysis of PiB distribution in Parkinson and Alzheimer diseases. Neurology 2013, 81:520-527.
12. Clinton L.K., Blurton-Jones M., Myczek K., Trojanowski J.Q., LaFerla F.M. Synergistic interactions between Abeta, tau, and alpha-synuclein: acceleration of neuropathology and cognitive decline. J.Neurosci. 2010, 30:7281-7289.
13. Compta Y., Marti M.J., Ibarretxe-Bilbao N., Junque C., Valldeoriola F., Munoz E., Ezquerra M., Rios J., Tolosa E. Cerebrospinal tau, phospho-tau, and beta-amyloid and neuropsychological functions in Parkinson's disease. Mov. Disord. 2009, 24:2203-2210.
14. Compta Y., Parkkinen L., O'Sullivan S.S., Vandrovcova J., Holton J.L., Collins C., Lashley T., Kallis C., Williams D.R., de Silva R., Lees A.J., Revesz T. Lewy- and Alzheimer-type pathologies in Parkinson's disease dementia: which is more important?. Brain 2011, 134(Pt 5):1493-1505.
15. Compta Y., Pereira J.B., Rios J., Ibarretxe-Bilbao N., Junque C., Bargallo N., Camara A., Buongiorno M., Fernandez M., Pont-Sunyer C., Marti M.J. Combined dementia-risk biomarkers in Parkinson's disease: a prospective longitudinal study. Parkinsonism Relat. Disord. 2013, 19:717-724.
16. Cools R. Dopaminergic modulation of cognitive function-implications for L-DOPA treatment in Parkinson's disease. Neurosci. Biobehav. Rev. 2006, 30:1-23.
17. Delis D.C., Kaplan E., Kramer J.H. Delis Kaplan Executive Function System 2001, The Psychological Corporation, San Antonio, TX.
18. Delis D., Kaplan E., Kramer J., Ober B. California Verbal Learning Test-II 2000, The Psychological Corporation, San Antonio, TX.
19. Edison P., Rowe C.C., Rinne J.O., Ng S., Ahmed I., Kemppainen N., Villemagne V.L., O'Keefe G., Nagren K., Chaudhury K.R., Masters C.L., Brooks D.J. Amyloid load in Parkinson's disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography. J.Neurol. Neurosurg. Psychiatry 2008, 79:1331-1338.
20. Emre M., Aarsland D., Brown R., Burn D.J., Duyckaerts C., Mizuno Y., Broe G.A., Cummings J., Dickson D.W., Gauthier S., Goldman J., Goetz C., Korczyn A., Lees A., Levy R., Litvan I., McKeith I., Olanow W., Poewe W., Quinn N., Sampaio C., Tolosa E., Dubois B. Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov. Disord. 2007, 22:1689-1707. quiz 837.
21. Fagan A.M., Mintun M.A., Mach R.H., Lee S.Y., Dence C.S., Shah A.R., LaRossa G.N., Spinner M.L., Klunk W.E., Mathis C.A., DeKosky S.T., Morris J.C., Holtzman D.M. Inverse relation between invivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann. Neurol. 2006, 59:512-519.
22. Foster E.R., Campbell M.C., Burack M.A., Hartlein J., Flores H.P., Cairns N.J., Hershey T., Perlmutter J.S. Amyloid imaging of Lewy body-associated disorders. Mov. Disord. 2010, 25:2516-2523.
23. Foulds P.G., Yokota O., Thurston A., Davidson Y., Ahmed Z., Holton J., Thompson J.C., Akiyama H., Arai T., Hasegawa M., Gerhard A., Allsop D., Mann D.M. Post mortem cerebrospinal fluid alpha-synuclein levels are raised in multiple system atrophy and distinguish this from the other alpha-synucleinopathies, Parkinson's disease and Dementia with Lewy bodies. Neurobiol. Dis. 2012, 45:188-195.
24. Goetz C.G., Tilley B.C., Shaftman S.R., Stebbins G.T., Fahn S., Martinez-Martin P., Poewe W., Sampaio C., Stern M.B., Dodel R., Dubois B., Holloway R., Jankovic J., Kulisevsky J., Lang A.E., Lees A., Leurgans S., LeWitt P.A., Nyenhuis D., Olanow C.W., Rascol O., Schrag A., Teresi J.A., van Hilten J.J., LaPelle N. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov. Disord. 2008, 23:2129-2170. Movement Disorder Society UPDRS Revision Task Force.
25. Gomperts S.N., Locascio J.J., Marquie M., Santarlasci A.L., Rentz D.M., Maye J., Johnson K.A., Growdon J.H. Brain amyloid and cognition in Lewy body diseases. Mov. Disord. 2012, 27:965-973.
26. Gomperts S.N., Rentz D.M., Moran E., Becker J.A., Locascio J.J., Klunk W.E., Mathis C.A., Elmaleh D.R., Shoup T., Fischman A.J., Hyman B.T., Growdon J.H., Johnson K.A. Imaging amyloid deposition in Lewy body diseases. Neurology 2008, 71:903-910.
27. Hall S., Ohrfelt A., Constantinescu R., Andreasson U., Surova Y., Bostrom F., Nilsson C., Hakan W., Decraemer H., Nagga K., Minthon L., Londos E., Vanmechelen E., Holmberg B., Zetterberg H., Blennow K., Hansson O. Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders. Arch. Neurol. 2012, 69:1445-1452.
28. Head D., Bugg J.M., Goate A.M., Fagan A.M., Mintun M.A., Benzinger T., Holtzman D.M., Morris J.C. Exercise engagement as a moderator oftheeffects of APOE genotype on amyloid deposition. Arch. Neurol. 2012, 69:636-643.
29. Hely M.A., Reid W.G., Adena M.A., Halliday G.M., Morris J.G. The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Mov. Disord. 2008, 23:837-844.
30. Hobson P., Meara J. Risk and incidence of dementia in a cohort of older subjects with Parkinson's disease in the United Kingdom. Mov. Disord. 2004, 19:1043-1049.
31. Hong Z., Shi M., Chung K.A., Quinn J.F., Peskind E.R., Galasko D., Jankovic J., Zabetian C.P., Leverenz J.B., Baird G., Montine T.J., Hancock A.M., Hwang H., Pan C., Bradner J., Kang U.J., Jensen P.H., Zhang J. DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain 2010, 133(Pt 3):713-726.
32. Huang Y. Mechanisms linking apolipoprotein E isoforms with cardiovascular and neurological diseases. Curr. Opin. Lipidol. 2010, 21:337-345.
33. Hughes A.J., Daniel S.E., Kilford L., Lees A.J. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J.Neurol. Neurosurg. Psychiatry 1992, 55:181-184.
34. Hurtig H.I., Trojanowski J.Q., Galvin J., Ewbank D., Schmidt M.L., Lee V.M., Clark C.M., Glosser G., Stern M.B., Gollomp S.M., Arnold S.E. Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson's disease. Neurology 2000, 54:1916-1921.
35. Ivnik R.J., Malec J.F., Smith G.E., Tangalos E.G., Petersen R.C. Neuropsychological tests' norms above age 55: COWAT, BNT, MAE token, WRAT-R reading, AMNART, STROOP, TMT, and JLO. Clin. Neuropsychol. 1996, 10:262-278.
36. Kang J.H., Irwin D.J., Chen-Plotkin A.S., Siderowf A., Caspell C., Coffey C.S., Waligorska T., Taylor P., Pan S., Frasier M., Marek K., Kieburtz K., Jennings D., Simuni T., Tanner C.M., Singleton A., Toga A.W., Chowdhury S., Mollenhauer B., Trojanowski J.Q., Shaw L.M. Association of cerebrospinal fluid beta-amyloid 1-42, T-tau, p-tau181, and alpha-synuclein levels with clinical features of drug-naive patients with early parkinson disease. JAMA Neurol. 2013, 70:1277-1287. the Parkinson's Progression Markers Initiative.
37. Kaplan E., Goodglass H., Weintraub S. Boston Naming Test 2001, Pro-ED, Austin, TX. second ed.
38. Klunk W.E., Engler H., Nordberg A., Wang Y., Blomqvist G., Holt D.P., Bergstrom M., Savitcheva I., Huang G.F., Estrada S., Ausen B., Debnath M.L., Barletta J., Price J.C., Sandell J., Lopresti B.J., Wall A., Koivisto P., Antoni G., Mathis C.A., Langstrom B. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann. Neurol. 2004, 55:306-319.
39. Korff A., Liu C., Ginghina C., Shi M., Zhang J. Alpha-synuclein in cerebrospinal fluid of Alzheimer's disease and mild cognitive impairment. J.Alzheimers Dis. 2013, 36:679-688. Alzheimer's Disease Neuroimaging Initiative.
40. Kotzbauer P.T., Cairns N.J., Campbell M.C., Willis A.W., Racette B.A., Tabbal S.D., Perlmutter J.S. Pathologic accumulation of alpha-synuclein and Abeta in Parkinson disease patients with dementia. Arch. Neurol. 2012, 69:1326-1331.
41. Kowal S.L., Dall T.M., Chakrabarti R., Storm M.V., Jain A. The current and projected economic burden of Parkinson's disease in the United States. Mov. Disord. 2013, 28:311-318.
42. Kruger R., Kuhn W., Muller T., Woitalla D., Graeber M., Kosel S., Przuntek H., Epplen J.T., Schols L., Riess O. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat. Genet. 1998, 18:106-108.
43. Lashley T., Holton J.L., Gray E., Kirkham K., O'Sullivan S.S., Hilbig A., Wood N.W., Lees A.J., Revesz T. Cortical alpha-synuclein load is associated with amyloid-beta plaque burden in a subset of Parkinson's disease patients. Acta Neuropathol. 2008, 115:417-425.
44. Lezak M.D. Neuropsychological Assessment 1995, Oxford University Press, Oxford.
45. Lezak M.D., Howieson D.B., Loring D. ACompendium of Tests and Assessment Techniques 2004, Oxford University Press, Oxford.
46. Maetzler W., Liepelt I., Reimold M., Reischl G., Solbach C., Becker C., Schulte C., Leyhe T., Keller S., Melms A., Gasser T., Berg D. Cortical PIB binding in Lewy body disease is associated with Alzheimer-like characteristics. Neurobiol. Dis. 2009, 34:107-112.
47. Maetzler W., Reimold M., Liepelt I., Solbach C., Leyhe T., Schweitzer K., Eschweiler G.W., Mittelbronn M., Gaenslen A., Uebele M., Reischl G., Gasser T., Machulla H.J., Bares R., Berg D. [11C]PIB binding in Parkinson's disease dementia. Neuroimage 2008, 39:1027-1033.
48. Masliah E., Rockenstein E., Veinbergs I., Sagara Y., Mallory M., Hashimoto M., Mucke L. Beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease. Proc. Natl. Acad. Sci. U.S.A 2001, 98:12245-12250.
49. Mathis C.A., Wang Y., Holt D.P., Huang G.F., Debnath M.L., Klunk W.E. Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. J.Med. Chem. 2003, 46:2740-2754.
50. Mawuenyega K.G., Sigurdson W., Ovod V., Munsell L., Kasten T., Morris J.C., Yarasheski K.E., Bateman R.J. Decreased clearance of CNS beta-amyloid in Alzheimer's disease. Science 2010, 330:1774.
51. Mintun M.A., Larossa G.N., Sheline Y.I., Dence C.S., Lee S.Y., Mach R.H., Klunk W.E., Mathis C.A., DeKosky S.T., Morris J.C. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology 2006, 67:446-452.
52. Mollenhauer B., El-Agnaf O.M., Marcus K., Trenkwalder C., Schlossmacher M.G. Quantification of alpha-synuclein in cerebrospinal fluid as a biomarker candidate: review of the literature and considerations for future studies. Biomarkers Med. 2010, 4:683-699.
53. Mollenhauer B., Locascio J.J., Schulz-Schaeffer W., Sixel-Doring F., Trenkwalder C., Schlossmacher M.G. Alpha-synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Lancet Neurol. 2011, 10:230-240.
54. Morris J.C. Clinical dementia rating: a reliable and valid diagnostic and staging measure for dementia of the Alzheimer type. Int. Psychogeriatr. 1997, 9(Suppl 1):173-176. discussion 7-8.
55. Narhi L., Wood S.J., Steavenson S., Jiang Y., Wu G.M., Anafi D., Kaufman S.A., Martin F., Sitney K., Denis P., Louis J.C., Wypych J., Biere A.L., Citron M. Both familial Parkinson's disease mutations accelerate alpha-synuclein aggregation. J.Biol. Chem. 1999, 274:9843-9846.
56. Newell K.L., Hyman B.T., Growdon J.H., Hedley-Whyte E.T. Application of the National Institute on Aging (NIA)-Reagan Institute criteria for the neuropathological diagnosis of Alzheimer disease. J.Neuropathol. Exp. Neurol. 1999, 58:1147-1155.
57. Pan S., Shi M., Jin J., Albin R.L., Lieberman A., Gearing M., Lin B., Pan C., Yan X., Kashima D.T., Zhang J. Proteomics identification of proteins in human cortex using multidimensional separations and MALDI tandem mass spectrometer. Mol. Cell. Proteomics 2007, 6:1818-1823.
58. Park M.J., Cheon S.M., Bae H.R., Kim S.H., Kim J.W. Elevated levels of alpha-synuclein oligomer in the cerebrospinal fluid of drug-naive patients with Parkinson's disease. J.Clin. Neurol. 2011, 7:215-222.
59. Parnetti L., Chiasserini D., Bellomo G., Giannandrea D., De Carlo C., Qureshi M.M., Ardah M.T., Varghese S., Bonanni L., Borroni B., Tambasco N., Eusebi P., Rossi A., Onofrj M., Padovani A., Calabresi P., El-Agnaf O. Cerebrospinal fluid Tau/alpha-synuclein ratio in Parkinson's disease and degenerative dementias. Mov. Disord. 2011, 26:1428-1435.
60. Parnetti L., Chiasserini D., Persichetti E., Eusebi P., Varghese S., Qureshi M.M., Dardis A., Deganuto M., De Carlo C., Castrioto A., Balducci C., Paciotti S., Tambasco N., Bembi B., Bonanni L., Onofrj M., Rossi A., Beccari T., El-Agnaf O., Calabresi P. Cerebrospinal fluid lysosomal enzymes and alpha-synuclein in Parkinson's disease. Mov. Disord. 2014, 29:1019-1027.
61. Parnetti L., Farotti L., Eusebi P., Chiasserini D., De Carlo C., Giannandrea D., Salvadori N., Lisetti V., Tambasco N., Rossi A., Majbour N.K., El-Agnaf O., Calabresi P. Differential role of CSF alpha-synuclein species, tau, and Abeta42 in Parkinson's disease. Front. Aging Neurosci. 2014, 6:53.
62. Pletnikova O., West N., Lee M.K., Rudow G.L., Skolasky R.L., Dawson T.M., Marsh L., Troncoso J.C. Abeta deposition is associated with enhanced cortical alpha-synuclein lesions in Lewy body diseases. Neurobiol. Aging 2005, 26:1183-1192.
63. Polymeropoulos M.H., Lavedan C., Leroy E., Ide S.E., Dehejia A., Dutra A., Pike B., Root H., Rubenstein J., Boyer R., Stenroos E.S., Chandrasekharappa S., Athanassiadou A., Papapetropoulos T., Johnson W.G., Lazzarini A.M., Duvoisin R.C., Di Iorio G., Golbe L.I., Nussbaum R.L. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997, 276:2045-2047.
64. Riedel O., Klotsche J., Spottke A., Deuschl G., Forstl H., Henn F., Heuser I., Oertel W., Reichmann H., Riederer P., Trenkwalder C., Dodel R., Wittchen H.U. Cognitive impairment in 873 patients with idiopathic Parkinson's disease. Results from the German Study on Epidemiology of Parkinson's Disease with Dementia (GEPAD). J.Neurol. 2008, 255:255-264.
65. Shi M., Bradner J., Hancock A.M., Chung K.A., Quinn J.F., Peskind E.R., Galasko D., Jankovic J., Zabetian C.P., Kim H.M., Leverenz J.B., Montine T.J., Ginghina C., Kang U.J., Cain K.C., Wang Y., Aasly J., Goldstein D., Zhang J. Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann. Neurol. 2011, 69:570-580.
66. Siderowf A., Xie S.X., Hurtig H., Weintraub D., Duda J., Chen-Plotkin A., Shaw L.M., Van Deerlin V., Trojanowski J.Q., Clark C. CSF amyloid {beta}1-42 predicts cognitive decline in Parkinson disease. Neurology 2010, 75:1055-1061.
67. Slaets S., Vanmechelen E., Le Bastard N., Decraemer H., Vandijck M., Martin J.J., De Deyn P.P., Engelborghs S. Increased CSF alpha-synuclein levels in Alzheimer's disease: correlation with tau levels. Alzheimers Dement 2014.
68. Tateno F., Sakakibara R., Kawai T., Kishi M., Murano T. Alpha-synuclein in the cerebrospinal fluid differentiates synucleinopathies (Parkinson disease, dementia with Lewy bodies, multiple system atrophy) from Alzheimer disease. Alzheimer Dis. 2012, 26:213-216.
69. Tokuda T., Qureshi M.M., Ardah M.T., Varghese S., Shehab S.A., Kasai T., Ishigami N., Tamaoka A., Nakagawa M., El-Agnaf O.M. Detection of elevated levels of alpha-synuclein oligomers in CSF from patients with Parkinson disease. Neurology 2010, 75:1766-1772.
70. Toledo J.B., Korff A., Shaw L.M., Trojanowski J.Q., Zhang J. CSF alpha-synuclein improves diagnostic and prognostic performance of CSF tau and Abeta in Alzheimer's disease. Acta Neuropathol. 2013, 126:683-697.
71. van Dijk K.D., Persichetti E., Chiasserini D., Eusebi P., Beccari T., Calabresi P., Berendse H.W., Parnetti L., van de Berg W.D. Changes in endolysosomal enzyme activities in cerebrospinal fluid of patients with Parkinson's disease. Mov. Disord. 2013, 28:747-754.
72. Vemuri P., Wiste H.J., Weigand S.D., Shaw L.M., Trojanowski J.Q., Weiner M.W., Knopman D.S., Petersen R.C., Jack C.R. MRI and CSF biomarkers in normal, MCI, and AD subjects: diagnostic discrimination and cognitive correlations. Neurology 2009, 73:287-293. Alzheimer's Disease Neuroimaging Initiative.
73. Wang Y., Shi M., Chung K.A., Zabetian C.P., Leverenz J.B., Berg D., Srulijes K., Trojanowski J.Q., Lee V.M., Siderowf A.D., Hurtig H., Litvan I., Schiess M.C., Peskind E.R., Masuda M., Hasegawa M., Lin X., Pan C., Galasko D., Goldstein D.S., Jensen P.H., Yang H., Cain K.C., Zhang J. Phosphorylated alpha-synuclein in Parkinson's disease. Sci. Transl. Med. 2012, 4:121ra20.
74. Wechsler D. Wechsler Adult Intelligence Scale III 1997, The Psychological Corporation, San Antonio, TX.
75. Wechsler D. Wechsler Memory Scale III 1997, The Psychological Corporation, San Antonio, TX.
76. Woodcock R.W., McGrew K.S., Mather N. Woodcock-Johnson Tests of Achievement 2001, Riverside Publishing Company, Itasca, IL.
77. Zhang J., Sokal I., Peskind E.R., Quinn J.F., Jankovic J., Kenney C., Chung K.A., Millard S.P., Nutt J.G., Montine T.J. CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases. Am. J. Clin. Pathol. 2008, 129:526-529.